Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?
DDR
MSI
PTEN
dMMR
mCRPC
precision medicine
prostate cancer
target therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Aug 2022
29 Aug 2022
Historique:
received:
10
08
2022
revised:
26
08
2022
accepted:
27
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Prostate cancer is the second most common diagnosed cancer and the fifth leading cause of cancer-related deaths in men worldwide. Despite significant advances in the management of castration-sensitive prostate cancer, the majority of patients develop a castration-resistant disease after a median duration of treatment of 18-48 months. The transition to a castrate resistance state could rely on alternative survival pathways, some related to androgen-independent mechanisms. Although several agents have been approved in this setting, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Recent studies revealed some of the complex pathways underlying inherited and acquired mechanisms of resistance to available treatments. A better understanding of these pathways may lead to significant improvements in survival by providing innovative therapeutic targets. The present comprehensive review attempts to provide an overview of recent progress in novel targeted therapies and near-future directions.
Identifiants
pubmed: 36077726
pii: cancers14174189
doi: 10.3390/cancers14174189
pmc: PMC9454420
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Front Oncol. 2014 Dec 23;4:370
pubmed: 25566507
Nature. 2012 Feb 22;485(7396):55-61
pubmed: 22367541
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Cancer Cell. 2020 Oct 12;38(4):489-499.e3
pubmed: 32916128
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
Clin Genitourin Cancer. 2019 Jun;17(3):201-208.e1
pubmed: 31056399
Lancet Oncol. 2021 Sep;22(9):1250-1264
pubmed: 34388386
Clin Cancer Res. 2009 Aug 1;15(15):4799-805
pubmed: 19638457
J Biol Chem. 2018 Jul 6;293(27):10524-10535
pubmed: 29599286
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409187
Lancet. 2021 Jul 10;398(10295):131-142
pubmed: 34246347
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
Nat Rev Genet. 2017 Oct;18(10):613-623
pubmed: 28649135
Eur Urol. 2020 Dec;78(6):822-830
pubmed: 32811715
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
J Clin Oncol. 2021 Jul 10;39(20):2294-2303
pubmed: 33914595
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Onco Targets Ther. 2021 Sep 15;14:4819-4832
pubmed: 34552338
Mol Cancer Ther. 2011 Dec;10(12):2426-36
pubmed: 21998291
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Oncotarget. 2017 Jul 10;8(39):65566-65576
pubmed: 29029453
Cancer Discov. 2018 Jun;8(6):764-779
pubmed: 29581176
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32788235
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
Prostate. 2020 Jan;80(1):99-108
pubmed: 31742767
Oncologist. 2017 May;22(5):503-e43
pubmed: 28314838
Lancet Oncol. 2019 May;20(5):686-700
pubmed: 30987939
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Res Rep Urol. 2021 Jun 30;13:457-472
pubmed: 34235102
Clin Cancer Res. 2017 Nov 15;23(22):6863-6874
pubmed: 28790115
N Engl J Med. 2022 Mar 24;386(12):1132-1142
pubmed: 35179323
Nat Commun. 2014 Sep 25;5:4988
pubmed: 25255306
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Cancer Genet Cytogenet. 2006 Sep;169(2):128-37
pubmed: 16938570
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Cancer Res. 2017 May 1;77(9):2179-2185
pubmed: 28432052
Cells. 2020 Oct 22;9(11):
pubmed: 33105713
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Curr Top Microbiol Immunol. 2010;347:241-62
pubmed: 20549474
DNA Repair (Amst). 2014 Jul;19:169-75
pubmed: 24746645
Eur Urol. 2017 Mar;71(3):417-425
pubmed: 27590317
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Cancer Discov. 2017 Jan;7(1):102-113
pubmed: 27872130